Adamantane and related compounds
Experimental small molecules built around the adamantane cage, including Chlodantane, Cyclontane and coded ADK compounds tested in pharmacology studies.
Findings from selected studies
- A Chlodantane analogue in mice
After 14 days, treadmill performance in mice receiving the camphane analogue rose by 23.22–25.20%. Groups differed at baseline, and the treated animals approached control running times.
Browse study findings by subject ↓
Chlodantane’s development history
New historical coverage traces the pharmacokinetic and toxicology record, Sirius University’s claim of clinical testing, and later publications including the 2025 gram-scale chemistry paper. Institutional statements and documented human-trial results are distinguished.
Read the Chlodantane history and source review ↗Chemical classes and preparation differences
Bromantane is an arylamine. Chlodantane and ADK-918 are benzamides; Cyclontane is a hydroxyadamantane. The newer camphane candidates change the cage framework. “Successor” describes a research interest here, not demonstrated superiority or regulatory approval.
Heat and cold formulation ↗
Chlodantane’s 2019 patent contains animal comparisons with Bemitil and Ladasten. The result depends on preparation, exposure and temperature.
Circadian-disruption formulation ↗
The 2018 Cyclontane–sodium oxybate patent studies a combination. Sleep recovery was incomplete, and its findings cannot be assigned to Cyclontane alone.
Neutral findings and study limitations
- 2022 attention experiment: the direction of the response depended on the mice’s starting attention phenotype.
- 2023 formulation comparison: water-soluble complexes lost activity in the reported tests. Greater solubility did not guarantee better performance.
- Historical enzyme screen: metabolic-enzyme effects are not evidence of beneficial detoxification or safe combinations.
From ADK codes to modern cage analogues
- 1989 filing / 1996 publication: the original Chlodantane–ADK-918 certificate is now identified; its experimental tables still need recovery.
- 2016–2017 flexible Bromantane analogues: synthesis, pharmacology and basicity papers extend the arylamine branch. Parts II and IV remain bibliographic leads pending full review.
- 2018 phenoxyacetamides and 2019 cage-amine synthesis: distinct structural modifications, not interchangeable preparations.
- 2023 camphane benzamides and 2024 camphane anilines: separate animal research branches addressing endurance and behavior.
Modern paper-specific compound numbers are not historical ADK codes. ADK numbering does not establish the library’s size, discovery order or a continuous institutional program. No service-member trial has been verified here for Chlodantane or Cyclontane.
Compound and archival records
Some entries are well-identified experimental candidates; others are screening codes awaiting original structural records. The number of records is not a count of clinically effective drugs.
| Record | Identity and scope | Sources |
|---|---|---|
| Chlodantane ↗ | N-(adamantan-2-yl)-4-chlorobenzamide (ADK-910), an experimental small molecule with an adamantane cage joined to a chlorobenzamide. Russian studies examined temperature stress and physical workload. | Date unverified · Dissertation abstract transcription ↗ 1996 · Dissertation abstract transcription ↗ Date unverified · Source record ↗ Date unverified · Source record ↗ Date unverified · Source record ↗ |
| Cyclontane ↗ | A synthetic adamantane derivative, also called ADK-638, studied on its own and in a formulation with sodium oxybate. | |
| ADK-918 ↗ | The para-bromobenzamide counterpart of Chlodantane, N-(adamantan-2-yl)-4-bromobenzamide. It is chemically distinct from Bromantane. | Date unverified · Dissertation abstract transcription ↗ |
| ADK-957 ↗ | An experimental adamantane chlorophenoxyacetamide. A 2019 chemistry paper identifies the compound and cites earlier cold-exposure research without reporting the original results. | |
| ADK-963 ↗ | A historical research code for an ortho-hydroxyphenyl aminoadamantane described in an immunology dissertation. The available description does not resolve its stereochemistry. | |
| ADK-613 ↗ | A historical research code for the hydrochloride of an adamantyl-substituted para-fluoroaniline. The identification comes from a dissertation on immune regulation. | |
| Kemantane ↗ | A synthetic adamantane compound studied in Russian immune research, including historical clinical reports. | Date unverified · Dissertation abstract transcription ↗ Date unverified · Source record ↗ Date unverified · Source record ↗ |
| Camphane chlorobenzamide ↗ | An experimental chlorobenzamide designed as a structural analogue of Chlodantane. It has a camphane cage in place of Chlodantane’s adamantane cage. | |
| Adamantylaminoethyl chlorophenoxyacetate ↗ | A synthetic adamantane-based ester described in Soviet patent SU1771186A1 for experimental temperature-stress research. | |
| ADK-559 ↗ | ADK-559 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent. | |
| ADK-591 ↗ | ADK-591 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent. | |
| ADK-676 ↗ | ADK-676 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent. | |
| ADK-677 ↗ | ADK-677 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent. | |
| ADK-790 ↗ | An experimental adamantane–benzimidazole compound studied for its effects on liver enzymes that metabolize drugs. | |
| ADK-828 ↗ | Adamantylidene-2,6-diacetonitrile, an experimental adamantane derivative. Animal studies examined induction of liver drug-metabolizing enzymes and anaphylactic reactions. | |
| ADK-829 ↗ | An experimental bromophenyl benzamide attached to an adamantane group, identified in a historical liver-enzyme screen. | |
| Camphane aniline 4e ↗ | A synthetic para-ethylphenyl camphane amine. Compound 4e is the designation used in a 2024 chemical study of structural analogues of Bromantane. |
What still needs recovery
The original RU2196575C2 Cyclontane experiments, the tables accompanying SU1646256A1, ADK-957’s original cold-exposure study, complete dissertation scans and independent safety/clinical research remain priorities. Shared filing dates or investigators do not by themselves prove a single coordinated development program.
View the Cyclontane combination in the research matrix ↗
Bibliography and source appraisal
Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures
Format: Patent · Reviewed: Selected animal experiments and formulation description reviewed
· RU2704126C2; filed 28 November 2016
The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.
Results and tables
Reported patent results
Reported findings
The formulation increased rod-retention time after cold stress but did not restore the intact-animal value.
Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
Population or model Male mice; treadmill tests at +40°C and −5°C
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cold-exposure motor coordination | 24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controls | Medians and quartiles; intact animals 127.0 (100.5–183.0) s · p=0.04 versus cold control |
| Sydnocarb comparator | 6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold control | Worse retention in this test; not general clinical inferiority · p=0.04 |
These findings concern a specific formulation and mouse model. They do not establish human occupational performance or protection under dangerous temperature exposure.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Male mice; treadmill tests at +40°C and −5°C
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Patent-reported animal results are not an independently replicated clinical trial or evidence of safe heat/cold exposure.
- The response was non-linear; formulation-specific effects cannot be assigned to every Chlodantane product.
- The groups were small, and the source gives conflicting comparison-group sizes.
Reviewed 2026-10-03.
Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis
Format: Patent · Reviewed: Selected methods and sleep-result passages reviewed
· RU2674342C2; filed 28 November 2016; Russian Federation represented by Ministry of Defense
The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.
Results and tables
Reported patent results
Reported findings
Some activity and REM-sleep measures improved relative to untreated desynchronization, while sleep timing remained abnormal.
Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
Population or model Rodent circadian-disruption experiments; 18-hour light/dark schedule
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Wheel activity | Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900 | Desynchronized rats · Third day |
| REM-sleep duration | Reported 1.7-fold longer than untreated desynchronization; 62.5% versus 30% exceeded the stated REM threshold | Threshold: REM duration >50% of the baseline group average |
| Persisting abnormality | REM-onset latency remained approximately twice baseline; wakefulness remained elevated | Improvement versus injury did not mean normalization |
| Acute observations | No deaths or listed overt neurological/behavioral abnormalities reported | Animal observations only · 14 days |
The combination does not isolate Cyclontane, and sleep comparisons vary by experiment. Animal safety observations do not establish human safety of this combination.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Rodent circadian-disruption experiments; 18-hour light/dark schedule
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety.
- No clinical sleep benefit or safe self-use regimen follows from these experiments.
Reviewed 2026-10-03.
Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability
Format: Journal article; full-text reproduction · Reviewed: Abstract, identity passage and selected methods reviewed
N. A. Sukhorukova, R. M. Salimov, G. I. Kovalev · Pharmacokinetics and Pharmacodynamics. 2022;(1):3–8
Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.
- Population / setting
- CD-1 mice separated by baseline attention phenotype; three administrations
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Phenotype-dependent mouse behavior is not evidence for human ADHD treatment or general cognitive enhancement.
- Dose, route and repeated-testing effects limit extrapolation; the names Cyclantane and Cyclontane refer here to ADK-638.
Reviewed 2026-10-03.
Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes
A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al. · Pharmaceutical Chemistry Journal. 57(4):523–534
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
- Population / setting
- Mouse pharmacology experiments
- Source reviewed
- Institute abstract and selected author-uploaded full-text passages checked, including the 7/14-day schedule and baseline-imbalance discussion; complete tables not independently appraised.
Study limitations
- Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
- An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose.
- The Russian and English versions are one publication, not independent replication.
Reviewed 2026-10-03.
Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes
I. A. Novakov, R. V. Brunilin, G. M. Butov, A. A. Vernigora, M. B. Navrotskii, A. S. Yablokov, S. N. Voloboev · Russian Journal of General Chemistry. 89(3):399–404
The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.
- Population / setting
- Chemical synthesis and characterization; background pharmacology citations
- Source reviewed
- Author-uploaded paper’s accessible chemistry/background passages checked; earlier pharmacology not independently recovered.
Study limitations
- Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy.
- ADK-957’s original cold-exposure experiment and detailed safety data remain acquisition targets.
Reviewed 2026-10-03.
Role of neurotropic adamantane-containing compounds in the regulation of immunity
· Dissertation; OCR reproduction
Format: Dissertation abstract transcription · Reviewed: See scope
· Dissertation author’s abstract; third-party Russian transcription
The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.
- Population / setting
- Multiple mouse strains and laboratory immune assays
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata.
- Immune and colony assays do not demonstrate better health, infection prevention or long-term stem-cell expansion in people.
Reviewed 2026-10-03.
Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
· Dissertation; OCR reproduction
Format: Dissertation abstract transcription · Reviewed: See scope
T. G. Khlopushina · Doctoral dissertation author’s abstract. Moscow, 1996
ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.
- Population / setting
- Mouse hepatic-enzyme screening and sensitized guinea-pig anaphylaxis experiments
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Original structures and tables require checking against the scan; transcription errors are possible.
- Enzyme induction does not establish detoxification benefits or predict safe human drug combinations.
- Animal anaphylaxis results are not evidence for treating allergy in people; proposed adjunct uses were development suggestions.
Reviewed 2026-10-03.
Para-chlorophenoxyacetic acid adamant-2-ylaminoethyl ester hydrochloride with claimed thermoprotective and psychostimulant activities
N. V. Klimova, T. D. Karpova, Sh. Karadzhaev, N. P. Bykov, N. I. Avdyunina, B. M. Pyatin, I. S. Morozov, G. V. Pushkar, I. M. Zinovyeva · SU1771186A1; filed 23 October 1990; published 10 November 1995
The patent identifies a distinct aminoethyl ester and claims thermoprotective and psychostimulant activity. It is not ADK-957’s amide and is not Chlodantane.
Results and tables
Reported patent results
Experimental results unavailable in the source
No experimental result can be responsibly transcribed from the accessed entry.
The accessed Google Patents entry supplies bibliographic identity for the thermoprotective ester but no readable experiment section.
Population or model Patent-described experimental compound
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thermoprotection or stimulation outcome | No extractable measured value in the accessed record | Claimed properties are not substituted for observed results |
The original scan is needed. No effect size, group size, exposure or clinical benefit is inferred from the title.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Patent-described experimental compound
- Source reviewed
- Patent identity, title, inventors and dates checked; quantitative pharmacology not appraised.
Study limitations
- Patent claims are not verified clinical findings; experimental magnitude and independent replication remain unassessed.
Reviewed 2026-10-03.
Original Cyclontane / ADK-638 patent trail
· RU2196575C2; cited in later RU2674342C2
The later patent cites this earlier Cyclontane development record. Original behavioral and toxicity comparisons require direct verification before numerical claims are reproduced.
Results and tables
Reported patent results
Findings described in words
The patent reports increased running-to-exhaustion performance and stimulant-related behavioral effects.
Original Cyclontane/ADK-638 animal pharmacology, including treadmill groups of 8 preselected rats.
Population or model Original experiments not independently recovered for this entry
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Treadmill performance | Significantly longer running-to-exhaustion at selected tested exposures | 8 rats per group; exact table means not transcribed |
| Behavioral pharmacology | Anti-cataleptic activity and stimulant-like responses described | Model-specific comparisons do not establish human superiority to Bromantane |
Preselected animal performance is not a human occupational outcome, and the patent’s clinical recommendations exceed the experiments. Findings belong to ADK-638 rather than every related cage compound.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Original experiments not independently recovered for this entry
- Source reviewed
- Prior-art citation followed from the 2018 patent; original retrieval unsuccessful.
Study limitations
- Bibliographic lead only; neither potency ratios nor toxicity estimates from secondary accounts are treated as verified here.
Reviewed 2026-10-03.
Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation
· SU1646256A1
The abstract claims protection during overheating, hypobaric hypoxia and water deprivation, and improved rat operant activity under fatigue. Filing dates to 13 July 1989; publication was 10 June 1996.
Results and tables
Reported patent results
Experimental results unavailable in the source
Experimental results could not be extracted from the accessed source; the later Chlodantane formulation patent is a separate disclosure.
The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
Population or model Preclinical research; no human efficacy established
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Original experimental outcomes | Not available in the accessed bibliographic entry | No animal survival percentage or human performance effect is invented |
The original certificate is unavailable. Whether it contains experimental results remains unknown.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Only the patent abstract and metadata were recovered; the two experimental tables remain unavailable.
- Abstract toxicity figures lack adequate species/route context here and are not used to rank safety.
Reviewed 2026-10-03.
Phenoxyacetamide structural analogues of Chlodantane and ADK-918
· RU2660654C1; Volgograd State Technical University
The patent explicitly identifies its two adamantane-containing phenoxyacetamides as structural analogues of ADK-910 and ADK-918. This documents a later medicinal-chemistry branch, not demonstrated clinical superiority.
Results and tables
Reported patent results
Reported findings
The disclosure reports synthesis yields; it does not supply a verified clinical adaptogenic result.
Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.
Population or model Preclinical research; no human efficacy established
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Analogue 1 recovery | 15.1 g, 85% yield | Manufacturing result for the newly claimed analogue, not Chlodantane or ADK-918 |
| Analogue 2 recovery | 80% yield; melting interval 94.5–95.0°C | A different new analogue; analytical characterization |
Chemical yields do not establish biological adaptogenic activity. The claimed compounds are structural analogues of the reference candidates, not the candidates themselves.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-10-03.
Potential synthetic adaptogens I: new N-[(adamantan-1-yl)methyl]aniline derivatives
· Russian Chemical Bulletin. 65:1336–1340
The authors prepared more conformationally flexible Bromantane analogues and studied how reaction conditions affected products and yields.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-10-03.
Potential Synthetic Adaptogens II: synthesis and pharmacological activity of conformationally labile Bromantane analogues
· Pharmaceutical Chemistry Journal. 50:781–787
Bibliographic record for the N-[(adamantan-1-yl)methyl]-4-bromoaniline series. Compound-specific pharmacological results await full-text appraisal.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-10-03.
Potential Synthetic Adaptogens IV: synthesis and study of basicity of new N-[(adamantan-1-yl)methyl]aniline derivatives
· Russian Journal of Organic Chemistry. 53(5):663–672
Publisher contents identify the basicity study. Brain penetration and clinical activity cannot be inferred from basicity measurements.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-10-03.
Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction
· Zhurnal Organicheskoi Khimii. 55(11):1781–1788
Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-10-03.
Psychotropic activity of N-(camphan-2-yl)anilines: new structural analogues of Bromantane
· Pharmacy & Pharmacology. 12(4):295–308
The Russian abstract identifies para-ethylphenyl compound 4e as a lead with anxiolytic-like activity and signals in novel-object recognition and extrapolation-escape tests in rodents.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Russian abstract and bibliography checked, not the complete experimental tables.
- This record follows the Russian 4e designation; the compound numbers in the two languages still need to be checked against the chemical structures. No human benefit or superiority is established.
Reviewed 2026-10-03.
Study findings by subject
20 source records
1990 · Study involving people
Kemantane in recurrent aphthous stomatitis
The authors reported faster lesion healing and longer remission in fibrous or scarring recurrent aphthous stomatitis. No effect size or time-to-healing figures appear in the abstract.
1991 · Comparison in people
Kemantane in tuberculosis patients with intercurrent respiratory viral infection
In the 14 treated patients, the authors reported increased T-cell counts and lymphocyte blast formation. T-cell functional activity showed a favorable trend. Untreated patients’ immune measures were unchanged or tended to decline.
1991 · Study involving people
Clinical pharmacokinetics of Kemantane in bronchial disease
Gas–liquid chromatography detected little parent compound in blood. The authors attributed this to first-pass metabolism and characterized exposure using the principal active metabolite.
2006 · Animal research
Experimental pharmacokinetics of actoprotective agents: Bromantane and Chlodantane
The dissertation describes two tissue-exchange groups for Chlodantane: brain, liver, testes, kidneys, lungs and skeletal muscle equilibrated relatively rapidly with plasma, while adipose tissue equilibrated slowly. Bromantane was described using three groups.
2001 · Animal research
Toxicological characterization of new psychotropic drugs of the actoprotector and nootropic classes
The author reports that preclinical dossiers including Chlodantane, Bromantane and Bromitil were submitted to the Pharmacological Committee and supported recommendation for clinical investigation. The same work describes dose-dependent reproductive and blood-cell effects in animals.
2023 · Lab research
Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors
The paper reports antiviral activity for a family of cage-amides in cell culture. Its lead compound 18a had a reported selectivity index of 18,214 against vaccinia. This is a distinct experimental compound, not a numerical clinical result for Chlodantane. Modelling suggested p37 as a possible target; the paper did not demonstrate direct target binding.
2025 · Laboratory analysis
A sustainable twist on the Ritter reaction: iron-based deep eutectic solvents as a green route to amide synthesis
The publication uses Chlodantane as a gram-scale demonstration of a reusable reaction medium for amide chemistry. It reports an 89% isolated yield for that demonstration and evaluates process sustainability. Its significance is continued chemical-method development and analytical characterization, rather than evidence of clinical effectiveness.
2025 · Animal research
Ladasten plus fabomotizole in a paraquat-induced parkinsonian mouse model
The combination improved motor-test performance relative to the paraquat-exposed control group, with the largest reported differences in the third week.
2022 · Animal research
Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability
Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.
2023 · Animal research
Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
Methods and source ↗ · Chlodantane · Bromantane · ADK-918 · Camphane chlorobenzamide
2019 · Laboratory analysis
Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes
The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.
Methods and source ↗ · Chlodantane · ADK-918 · ADK-957 · Camphane chlorobenzamide
Animal research
Role of neurotropic adamantane-containing compounds in the regulation of immunity
The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.
Methods and source ↗ · Kemantane · Bromantane · Chlodantane · ADK-918 · ADK-963 · ADK-613
1996 · Animal research
Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.
Methods and source ↗ · Bromantane · Chlodantane · ADK-918 · ADK-559 · ADK-591 · ADK-676 · ADK-677 · ADK-790 · ADK-828 · ADK-829
2016 · Laboratory analysis
Potential synthetic adaptogens I: new N-[(adamantan-1-yl)methyl]aniline derivatives
The authors prepared more conformationally flexible Bromantane analogues and studied how reaction conditions affected products and yields.
2017 · Research record
Potential Synthetic Adaptogens II: synthesis and pharmacological activity of conformationally labile Bromantane analogues
Bibliographic record for the N-[(adamantan-1-yl)methyl]-4-bromoaniline series. Compound-specific pharmacological results await full-text appraisal.
2017 · Laboratory analysis
Potential Synthetic Adaptogens IV: synthesis and study of basicity of new N-[(adamantan-1-yl)methyl]aniline derivatives
Publisher contents identify the basicity study. Brain penetration and clinical activity cannot be inferred from basicity measurements.
2019 · Laboratory analysis
Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction
Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.
Methods and source ↗ · Bromantane · Chlodantane · Camphane chlorobenzamide
2024 · Animal research
Psychotropic activity of N-(camphan-2-yl)anilines: new structural analogues of Bromantane
The Russian abstract identifies para-ethylphenyl compound 4e as a lead with anxiolytic-like activity and signals in novel-object recognition and extrapolation-escape tests in rodents.
1995 · Animal research
Pharmacokinetics of adamantane-derived actoprotectors: Bromitil experiments
The dissertation contents and reproduced conclusions identify a Bromitil pharmacokinetic section. The formulation is discussed as combined Bromantane and Bemitil.
1999 · Review of earlier studies
Adamantane derivatives enhancing body's resistance to emergencies
Summarizes screening of adamantane derivatives and distinguishes Bromantane from the chemically different Chlodantane.